Jeffrey S. Chamberlain, PhD, on Regulating DMD Gene Therapy Clinical Trials

Video

The professor and director of the Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center at University of Washington School of Medicine discussed working with the FDA toward a first disease-modifying therapy approval in Duchenne.

“It’s an exciting time, there's a lot of breakthroughs happening and new approaches to therapy, and the FDA is pretty receptive to getting as much input as they can to help them evaluate and grant approvals. They’re trying to speed things up and be able to grant early approval based on surrogate endpoints so that we can have an impact on these very serious disorders that have enormous impact on kids and other patients worldwide.”

Microdystrophin is used by clinical trials in the accelerated approval pathway assessing therapies for Duchenne muscular dystrophy (DMD) as a surrogate endpoint. A recent paper published in Human Gene Therapy reviewed its use as a surrogate endpoint in gene therapy trials in DMD. The authors, including first author Jeffrey S. Chamberlain, PhD, Professor and McCaw Chair, Muscular Dystrophy, and director, Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, concluded that it is a valid endpoint that correlates with clinical benefits in preclinical mouse studies.

CGTLive spoke with Chamberlain to learn more about challenges in regulating gene therapies for diseases like DMD. He discussed the importance of staying in communication with the FDA when working toward the approval of novel therapies.

REFERENCE
Chamberlain J, Robb M, Braun S, et al. Micro-dystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials. Human Gene Therapy. Published online January 24, 2023. http://doi.org/10.1089/hum.2022.190
Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
© 2024 MJH Life Sciences

All rights reserved.